A CE-certified enduring activity jointly provided by Rutgers Biomedical and Health Sciences and Spire Learning.
This activity is supported by educational grants from Genmab US, Inc., Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.
Despite advances in the treatment of non-small cell lung cancer (NSCLC), overall 5-year survival has not significantly improved in recent years. Newly approved and emerging immune checkpoint inhibitor (ICI) therapies offer improvements in survival over chemotherapy alone, but toxicities and immune-related adverse events (irAEs) must be anticipated and managed for successful treatment. In this educational activity, faculty members review the role of PD-L1 testing to determine the best approach to ICI therapy, current efficacy and safety data for ICI therapies in NSCLC, and how to identify and mitigate irAEs. They evaluate clinical trial data, along with patient- and disease-related factors, that allow for the individualization of therapy selection to promote optimal patient outcomes.
After completing this self assessment, you will receive an email directing you to one or more reinforcement activities which will review key teaching points, based on unique educational gaps uncovered in the program.
Oncology physicians, nurse practitioners, physician assistants; pulmonary physicians, nurse practitioners, physician assistants; pathologists and pharmacists
Upon completion of this activity, learners should be better able to:
- INTEGRATE optimal testing strategies for PD-L1 in NSCLC with patient-specific characteristics to offer the most appropriate and effective treatment regimens
- EVALUATE recent evidence for current and investigational ICIs used in monotherapy and combination regimens for NSCLC
- IMPLEMENT evidence-based and guideline-directed strategies to accurately identify and mitigate irAEs associated with ICI therapy
In support of improving patient care, this activity has been planned and implemented by Rutgers Biomedical and Health Sciences and Spire Learning. Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physicians: Rutgers Biomedical and Health Sciences designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Advanced practice nurses, nurses, and physician assistants may participate in this educational activity and earn a letter of attendance as AANP, ANCC and AAPA accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
HOW TO RECEIVE CREDIT
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page. Physicians should claim only those credits that reflect the time actually spent in the activity.
To receive credit for your participation in this educational activity:
- Read the learning objectives, disclosure statements and other introductory CME information
- Complete the preassessment prior to the start of the activity
- Participate in the online enduring activity
- Complete the postassessment with a passing grade of 70% or higher and the evaluation at the conclusion of the activity
If you are seeking credit, you must complete the postassessment and evaluation at the conclusion of the activity.
For information about the accreditation of this activity, please contact Rutgers Biomedical and Health Sciences (RBHS) at email@example.com.
CONFLICT OF INTEREST STATEMENT
In accordance with the disclosure policies of Rutgers Biomedical and Health Sciences (RBHS) and to conform with Joint Accreditation requirements and FDA guidelines, all individuals in a position to control the content of this educational activity are required to disclose to the activity participants the existence of any relevant relationships with entities producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exception of non-profit or government organizations and non-health care related companies, within the past 12 months.
In order to ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, RBHS has resolved all potential and real conflicts of interest through content review by a non-conflicted, qualified reviewer.FACULTY
Hossein Borghaei, DO, MS
Chief of Thoracic Medical Oncology
Professor, Department of Oncology/Hematology
Co-Director, Immune Monitoring Facility
The Gloria and Edmund M. Dunn Chair in Thoracic Malignancies
Fox Chase Cancer Center
Dr Borghaei has disclosed the following relevant financial relationships.
Consultant: AbbVie; Amgen Inc; AstraZeneca; Axiom; BioNTech; Boehringer Ingelheim Pharmaceuticals, Inc; Bristol Myers Squibb; Cantargia AB; Celgene Corporation; Daiichi Sankyo, Inc; Eli Lilly and Company; EMD Serono, Inc; Genentech, Inc; Genmab US, Inc; GLG Pharma, Inc; Huya Bioscience International, LLC; Merck and Co, Inc; Novartis Pharmaceuticals Corporation; Pfizer Inc; PharmaMar; Regeneron Pharmaceuticals, Inc; Takeda Pharmaceutical Company Limited
Grant/Research Support: Bristol Myers Squibb/Eli Lilly and Company; Merck and Co, Inc/Celgene Corporation; Millennium Pharmaceuticals, Inc
Scientific Advisory Board (Stock Options): Nucleai; Rgenix, Inc; Sonnet BioTherapeutics
Data Safety and Monitoring Board: Incyte Corp; Takeda Pharmaceutical Company Limited; University of Pennsylvania CAR-T Program
Other Financial Support - Honoraria: Amgen Inc; Daiichi Sankyo, Inc; Pfizer Inc
Other Financial Support - Travel: Amgen Inc; Bristol Myers Squibb; Eli Lilly and Company; EMD Serono, Inc; Genentech, Inc; Merck and Co, Inc
Kurt A. Schalper, MD, PhD
Assistant Professor of Pathology and Medicine (Medical Oncology)
Yale School of Medicine
Director, Translational Immuno-oncology Laboratory
Yale Cancer Center
New Haven, CT
Dr Schalper has disclosed the following relevant financial relationships.
Consultant: Clínica Alemana; EMD Serono, Inc; Merck & Co, Inc; Takeda Pharmaceutical Company Limited; Torque Therapeutics, Inc
Grant/Research Support: AstraZeneca; Bristol Myers Squibb; Eli Lilly and Company; Genentech, Inc/Roche; Merck & Co, Inc; Moderna, Inc; Navigate BioPharma Services, Inc; Pierre Fabre Group; Ribon Therapeutics; Surface Oncology; Takeda Pharmaceutical Company Limited; TESARO, Inc/GlaxoSmithKline
Speakers Bureau: Bristol Myers Squibb; Genmab US, Inc; Merck & Co, Inc; PeerView, Inc; Takeda Pharmaceutical Company Limited
Scientific Advisory Board: Agenus Inc; Shattuck Labs, Inc
Rutgers Biomedical and Health Sciences
Patrick Dwyer, Director, Continuing Medical Education, has no relevant financial relationships to disclose.
This activity has been peer-reviewed for relevance, accuracy of content, and balance of presentation by:
Jian Cao, PhD
Assistant Professor of Medicine
Rutgers Robert Wood Johnson Medical School
Rutgers Cancer Institute of New Jersey
New Brunswick, NJ
Jian Cao, PhD, has no relevant financial relationships to disclose.
This activity has been pilot-tested for time required for participation by Stephen Kranick, MD, Medicine Chief Resident, Rutgers Robert Wood Johnson Medical School; Noah Mahpour, MD, Medicine Chief Resident, Rutgers Robert Wood Johnson Medical School; and Scott Ventre, DO, Medicine Chief Resident, Rutgers Robert Wood Johnson Medical School. The testers have no relevant financial relationships to disclose.
Allison Goldberg, MPA, Director, Grants and Education, Austin Ulrich, PharmD, BCACP, Medical Writer, and Mairead Early, Program Manager, have no relevant financial relationships to disclose.
Christopher Washburn, PhD, Clinical Director, has disclosed the following relevant financial relationships: Employee/Spouse: Janssen Pharmaceuticals, Inc
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Rutgers Biomedical and Health Sciences and Spire Learning do not recommend the use of any agent outside of the labeled indications.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The opinions expressed in this educational activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of any manufacturer of pharmaceuticals or devices, or RBHS, or Spire Learning, LLC.
It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information.
Spire Learning, LLC, and RBHS will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication or activity, including any claims related to the products, drugs, or services mentioned herein.
Rutgers Biomedical and Health Sciences
Please direct content or CE related questions or concerns to RBHS Center for Continuing and Outreach Education (CCOE) by email firstname.lastname@example.org.
For technical support, please email email@example.com
Spire Learning, LLC, is committed to protecting the privacy of personal information from our participants and educational collaborators. Spire maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of personal information.
Collection and Use of Your Personal Information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing an activity. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of each activity. All evaluative information submitted is collected and retained, and used by Spire Learning, LLC, to continuously improve the learning experience.
Spire Learning, LLC, will not transfer, sell, or share personal information with outside parties or otherwise disclose personal information unless required to in a legal process. Spire will retain your personal data only for the period necessary to accomplish the stated purposes and to comply with applicable laws.
Copyright © 2021 by Spire Learning, LLC and Rutgers Biomedical and Health Sciences. All rights reserved including translation into other languages. No part of this publication or activity may be reproduced or transmitted in any form, by any means, without prior written permission of Spire Learning, LLC.
COURSE VIEWING REQUIREMENTS
|Supported Browsers: |
Google Chrome 60 or higher
Mozilla Firefox 60 or higher
Apple Safari 11.0 or higher
For video, install the latest version of Quicktime.
|Supported Phones & Tablets: |
iOS 9.3 and higher
Android 7.0 (Nougat or higher)
Microsoft Windows 8
|Additional Recommendations and Requirements |
|Display Resolution & Color Depth ||Resolution |
- 960 X 768 minimum
- 1024 X 768 recommended min.
- 8 bits (256 colors) minimum
- 16 bits (High colors) minimum
|Audio ||- Microphone |
- Speakers or headphones
- Audio recording support
|Word Processing ||Software that can open, modify, and save documents in Rich Text Format (RTF). Microsoft Word and PowerPoint are recommended. |